secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001420720-25-000018
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide
--------------------------------------------------------------------------------

- IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.
- Activin E monotherapy in obese mice: ~4% weight loss, 18% fat reduction vs placebo after two weeks.
- Activin E + semaglutide combination: 34% total weight loss (9% above semaglutide alone), 72% body fat reduction by DEXA.
- Both candidates target obesity and cardiometabolic diseases; IBIO-600 is anti-myostatin, Activin E induces fat-selective weight loss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/0001420720-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/ibio-20250408x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer